<p>Aquestive Therapeutics, Inc.（納斯達克代碼：AQST - 免費報告）- HC Wainwright 在 2023 年 3 月 10 日星期一發布的研究報告中對 Aquestive Therapeutics 的 2026 財年每股收益進行了預測。HC Wainwright 的分析師 R. Selvaraju 預計該公司將發佈每股收益（$0.56）。HC Wainwright 對該股票給予 “買入” 評級，目標價為 10.00 美元。市場普遍預計 Aquestive Therapeutics 當前全年的每股收益為（$0.46）。</p>
<p>獲取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
<p>Aquestive Therapeutics（納斯達克代碼：AQST - 獲取免費報告）最近在 2023 年 3 月 5 日星期三發佈了季度財報。該公司報告季度每股收益為（$0.19），低於分析師普遍預期的（$0.14），差距為（$0.05）。該公司在本季度的收入為 1187 萬美元，而分析師預期為 1311 萬美元。</p>
<p>其他一些股票研究分析師最近也對該股票發表了看法。Cantor Fitzgerald 在 2023 年 12 月 17 日星期二對 Aquestive Therapeutics 的股票進行了覆蓋，給予 “增持” 評級，目標價為 17.00 美元。Raymond James 在週五對 Aquestive Therapeutics 設定了 7.00 美元的目標價。Lake Street Capital 在週五將其對 Aquestive Therapeutics 的目標價從 10.00 美元下調至 8.00 美元，並給予該股票 “買入” 評級。最後，Alliance Global Partners 在週五的研究報告中重申了對 Aquestive Therapeutics 的 “買入” 評級。八位研究分析師對該股票給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，Aquestive Therapeutics 目前的共識評級為 “買入”，共識目標價為 10.57 美元。</p>
<p><strong>閲讀我們對 Aquestive Therapeutics 的最新股票分析</strong></p>
<h2>Aquestive Therapeutics 股票表現</h2>
<p>納斯達克代碼：AQST 的股票在週二開盤價為 2.54 美元。該公司的 50 日移動平均線為 3.07 美元，200 日移動平均線為 4.09 美元。Aquestive Therapeutics 的 1 年最低價為 2.24 美元，1 年最高價為 6.23 美元。該股票的市值為 2.5113 億美元，市盈率為-5.64，貝塔值為 2.76。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近增加或減少了對該公司的持股。美國銀行在第四季度將其在 Aquestive Therapeutics 的持股增加了 905.2%。美國銀行目前擁有 690,284 股該公司的股票，價值 245.7 萬美元，此前在上個季度增持了 621,614 股。State Street Corp 在第三季度將其在 Aquestive Therapeutics 的持股增加了 52.1%。State Street Corp 目前擁有 1,496,739 股該公司的股票，價值 745.4 萬美元，此前在此期間購買了 512,682 股。Stifel Financial Corp 在第四季度將其在 Aquestive Therapeutics 的持股增加了 315.4%。Stifel Financial Corp 目前擁有 398,561 股該公司的股票，價值 141.9 萬美元，此前在上個季度增持了 302,617 股。Harvey Capital Management Inc.在第四季度將其在 Aquestive Therapeutics 的持股增加了 1,419.3%。Harvey Capital Management Inc.目前擁有 267,390 股該公司的股票，價值 95.2 萬美元，此前在此期間增持了 249,790 股。最後，Verition Fund Management LLC 在第三季度購買了價值 99.5 萬美元的 Aquestive Therapeutics 新股。機構投資者和對沖基金持有該公司 32.45% 的股票。</p>
<h2>關於 Aquestive Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Aquestive Therapeutics, Inc.是一家在美國及國際上運營的製藥公司。該公司市場銷售 Sympazan，一種用於治療 Lennox-Gastaut 綜合症的口服可溶膜製劑；Suboxone，一種用於治療阿片類藥物依賴的舌下膜製劑；Zuplenz，一種用於治療與化療和術後恢復相關的噁心和嘔吐的口服可溶膜製劑；以及 Azstarys，一種用於治療注意力缺陷多動障礙的每日一次產品。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過了 Aquestive Therapeutics</li>
<li>什麼使一隻股票成為優秀的分紅股票？</li>
<li>過去 12 個月中回購收益率極高的 3 只股票</li>
<li>萬億美元市值的意義超越了數字</li>
<li>隨着經濟衰退擔憂加劇，三大公用事業股票強勁上漲</li>
<li>低市盈率增長股票：開啓投資機會</li>
<li>隱藏的寶石：5 只低於 10 美元的股票具有巨大的增長潛力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Aquestive Therapeutics 嗎？</h2>
<p>在你考慮投資 Aquestive Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Aquestive Therapeutics 並不在名單上。</p>
<p>雖然目前分析師對 Aquestive Therapeutics 的評級為 “買入”，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AQST

<p>HC Wainwright 分析師 R. Selvaraju 預測，Aquestive Therapeutics, Inc.（NASDAQ:AQST）將在 2026 財年報告每股收益為（$0.56）。該公司維持 “買入” 評級，目標價為 $10.00。目前市場對該公司收益的共識預期為每股（$0.46）。最近，該公司報告的季度每股收益為（$0.19），未能達到預期。機構投資者已增加對該公司的持股，該公司的市值為 2.5113 億美元，市盈率為 -5.64</p>

<p>Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.56) for the year. HC Wainwright has a &#34;Buy&#34; rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share.</p>
<div class="lb-trans"><p>Aquestive Therapeutics, Inc.（納斯達克代碼：AQST - 免費報告）- HC Wainwright 在 2023 年 3 月 10 日星期一發布的研究報告中對 Aquestive Therapeutics 的 2026 財年每股收益進行了預測。HC Wainwright 的分析師 R. Selvaraju 預計該公司將發佈每股收益（$0.56）。HC Wainwright 對該股票給予 “買入” 評級，目標價為 10.00 美元。市場普遍預計 Aquestive Therapeutics 當前全年的每股收益為（$0.46）。</p>
</div><p>Get <strong>Aquestive Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aquestive Therapeutics</strong> 的提醒：</p>
</div><p>Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million during the quarter, compared to analyst estimates of $13.11 million.</p>
<div class="lb-trans"><p>Aquestive Therapeutics（納斯達克代碼：AQST - 獲取免費報告）最近在 2023 年 3 月 5 日星期三發佈了季度財報。該公司報告季度每股收益為（$0.19），低於分析師普遍預期的（$0.14），差距為（$0.05）。該公司在本季度的收入為 1187 萬美元，而分析師預期為 1311 萬美元。</p>
</div><p>A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an &#34;overweight&#34; rating and a $17.00 price objective for the company. Raymond James set a $7.00 target price on Aquestive Therapeutics in a report on Friday. Lake Street Capital cut their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a report on Friday. Finally, Alliance Global Partners restated a &#34;buy&#34; rating on shares of Aquestive Therapeutics in a research report on Friday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $10.57.</p>
<div class="lb-trans"><p>其他一些股票研究分析師最近也對該股票發表了看法。Cantor Fitzgerald 在 2023 年 12 月 17 日星期二對 Aquestive Therapeutics 的股票進行了覆蓋，給予 “增持” 評級，目標價為 17.00 美元。Raymond James 在週五對 Aquestive Therapeutics 設定了 7.00 美元的目標價。Lake Street Capital 在週五將其對 Aquestive Therapeutics 的目標價從 10.00 美元下調至 8.00 美元，並給予該股票 “買入” 評級。最後，Alliance Global Partners 在週五的研究報告中重申了對 Aquestive Therapeutics 的 “買入” 評級。八位研究分析師對該股票給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，Aquestive Therapeutics 目前的共識評級為 “買入”，共識目標價為 10.57 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Aquestive Therapeutics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Aquestive Therapeutics 的最新股票分析</strong></p>
</div><h2>Aquestive Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Aquestive Therapeutics 股票表現</h2>
</div><p>Shares of NASDAQ:AQST opened at $2.54 on Tuesday. The company's fifty day moving average is $3.07 and its two-hundred day moving average is $4.09. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The stock has a market capitalization of $251.13 million, a price-to-earnings ratio of -5.64 and a beta of 2.76.</p>
<div class="lb-trans"><p>納斯達克代碼：AQST 的股票在週二開盤價為 2.54 美元。該公司的 50 日移動平均線為 3.07 美元，200 日移動平均線為 4.09 美元。Aquestive Therapeutics 的 1 年最低價為 2.24 美元，1 年最高價為 6.23 美元。該股票的市值為 2.5113 億美元，市盈率為-5.64，貝塔值為 2.76。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after acquiring an additional 621,614 shares in the last quarter. State Street Corp boosted its position in shares of Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company's stock valued at $7,454,000 after purchasing an additional 512,682 shares during the period. Stifel Financial Corp increased its position in shares of Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock worth $1,419,000 after acquiring an additional 302,617 shares in the last quarter. Harvey Capital Management Inc. raised its holdings in shares of Aquestive Therapeutics by 1,419.3% during the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock valued at $952,000 after acquiring an additional 249,790 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter valued at $995,000. Institutional investors and hedge funds own 32.45% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對該公司的持股。美國銀行在第四季度將其在 Aquestive Therapeutics 的持股增加了 905.2%。美國銀行目前擁有 690,284 股該公司的股票，價值 245.7 萬美元，此前在上個季度增持了 621,614 股。State Street Corp 在第三季度將其在 Aquestive Therapeutics 的持股增加了 52.1%。State Street Corp 目前擁有 1,496,739 股該公司的股票，價值 745.4 萬美元，此前在此期間購買了 512,682 股。Stifel Financial Corp 在第四季度將其在 Aquestive Therapeutics 的持股增加了 315.4%。Stifel Financial Corp 目前擁有 398,561 股該公司的股票，價值 141.9 萬美元，此前在上個季度增持了 302,617 股。Harvey Capital Management Inc.在第四季度將其在 Aquestive Therapeutics 的持股增加了 1,419.3%。Harvey Capital Management Inc.目前擁有 267,390 股該公司的股票，價值 95.2 萬美元，此前在此期間增持了 249,790 股。最後，Verition Fund Management LLC 在第三季度購買了價值 99.5 萬美元的 Aquestive Therapeutics 新股。機構投資者和對沖基金持有該公司 32.45% 的股票。</p>
</div><h2>About Aquestive Therapeutics</h2>
<div class="lb-trans"><h2>關於 Aquestive Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.</p>
<div class="lb-trans"><p>Aquestive Therapeutics, Inc.是一家在美國及國際上運營的製藥公司。該公司市場銷售 Sympazan，一種用於治療 Lennox-Gastaut 綜合症的口服可溶膜製劑；Suboxone，一種用於治療阿片類藥物依賴的舌下膜製劑；Zuplenz，一種用於治療與化療和術後恢復相關的噁心和嘔吐的口服可溶膜製劑；以及 Azstarys，一種用於治療注意力缺陷多動障礙的每日一次產品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Aquestive Therapeutics</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>3 Stocks With Sky-High Buyback Yields Over the Last 12 Months</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Top 3 Utilities Stocks Powering Up as Recession Fears Rise</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過了 Aquestive Therapeutics</li>
<li>什麼使一隻股票成為優秀的分紅股票？</li>
<li>過去 12 個月中回購收益率極高的 3 只股票</li>
<li>萬億美元市值的意義超越了數字</li>
<li>隨着經濟衰退擔憂加劇，三大公用事業股票強勁上漲</li>
<li>低市盈率增長股票：開啓投資機會</li>
<li>隱藏的寶石：5 只低於 10 美元的股票具有巨大的增長潛力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVFTVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AQST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aquestive Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Aquestive Therapeutics 嗎？</h2>
</div><p>Before you consider Aquestive Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Aquestive Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Aquestive Therapeutics 並不在名單上。</p>
</div><p>While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然目前分析師對 Aquestive Therapeutics 的評級為 “買入”，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

分析師對 Aquestive Therapeutic 2026 財年收益的預測